Li SX, Guo Y. Gut microbiome: New perspectives for type 2 diabetes prevention and treatment. World J Clin Cases 2023; 11(31): 7508-7520 [PMID: 38078135 DOI: 10.12998/wjcc.v11.i31.7508]
Corresponding Author of This Article
Yan Guo, MD, Professor, School of Clinical Medicine, Changchun University of Traditional Chinese Medicine, No. 1035 Boshuo Road, Nanguan District, Changchun 130000, Jilin Province, China. ccguoyan@163.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2023; 11(31): 7508-7520 Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7508
Gut microbiome: New perspectives for type 2 diabetes prevention and treatment
Shu-Xiao Li, Yan Guo
Shu-Xiao Li, Yan Guo, School of Clinical Medicine, Changchun University of Traditional Chinese Medicine, Changchun 130000, Jilin Province, China
Author contributions: Li SX analyzed the data, wrote and reviewed the manuscript; Guo Y reviewed the manuscript; all authors have read and approve the final manuscript.
Supported byJilin Provincial Science and Technology Department, No. 20210204029YY; and Jilin Provincial Natural Science Foundation Projects, No. YDZJ202201ZYTS151.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Guo, MD, Professor, School of Clinical Medicine, Changchun University of Traditional Chinese Medicine, No. 1035 Boshuo Road, Nanguan District, Changchun 130000, Jilin Province, China. ccguoyan@163.com
Received: August 25, 2023 Peer-review started: August 25, 2023 First decision: September 19, 2023 Revised: September 19, 2023 Accepted: October 23, 2023 Article in press: October 23, 2023 Published online: November 6, 2023 Processing time: 73 Days and 0.7 Hours
Abstract
Type 2 diabetes mellitus (T2DM), which is distinguished by increased glucose levels in the bloodstream, is a metabolic disease with a rapidly increasing incidence worldwide. Nevertheless, the etiology and characteristics of the mechanism of T2DM remain unclear. Recently, abundant evidence has indicated that the intestinal microbiota is crucially involved in the initiation and progression of T2DM. The gut microbiome, the largest microecosystem, engages in material and energy metabolism in the human body. In this review, we concentrated on the correlation between the gut flora and T2DM. Meanwhile, we summarized the pathogenesis involving the intestinal flora in T2DM, as well as therapeutic approaches aimed at modulating the gut microbiota for the management of T2DM. Through the analysis presented here, we draw attention to further exploration of these research directions.
Core Tip: In this review, we summarized the pathogenesis that intestinal flora is involved in type 2 diabetes mellitus (T2DM), as well as therapeutic approaches aimed at modulating the gut microbial for the management of T2DM.
